Can you provide a comprehensive overview of nephrotic syndrome, including its diagnosis and management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nephrotic Syndrome: Diagnosis to Management

Definition and Diagnostic Criteria

Nephrotic syndrome is diagnosed when you have nephrotic-range proteinuria (uPCR ≥200 mg/mmol or ≥2 g/g) plus either hypoalbuminemia (serum albumin <30 g/L) or edema when albumin is unavailable 1, 2.

Key Diagnostic Features:

  • Proteinuria: uPCR ≥200 mg/mmol (2 g/g) in spot urine, or ≥1000 mg/m² per day in 24-hour collection (dipstick 3+ or 4+)
  • Hypoalbuminemia: Serum albumin <30 g/L (3 g/dL)
  • Edema: Periorbital (morning) or dependent pitting edema (later in day) 3
  • Hyperlipidemia: Commonly present but not required for diagnosis

Response Definitions You Must Know:

Complete remission: uPCR ≤200 mg/g (negative/trace dipstick) on 3+ consecutive days 2

Partial remission: uPCR >200 mg/g but <2 g/g with serum albumin ≥30 g/L 2

Relapse: Recurrence of nephrotic-range proteinuria (dipstick ≥3+ for 3 consecutive days) after achieving complete remission 2

Initial Diagnostic Workup

Confirm the Diagnosis:

  1. Quantify proteinuria: Use urine PCR or ACR (PCR >300-350 mg/mmol indicates nephrotic range) 3
  2. Measure serum albumin and lipid panel
  3. Check renal function: Serum creatinine, eGFR

Search for Secondary Causes:

  • Blood glucose/HbA1c: Diabetic nephropathy (most common systemic cause) 3
  • Autoimmune workup: ANA, complement levels, anti-dsDNA for SLE
  • Infection screen: Hepatitis B/C, HIV
  • Malignancy screen: Age-appropriate cancer screening, serum/urine protein electrophoresis
  • Medication review: NSAIDs, gold, penicillamine, lithium 4

Age-Specific Etiologies:

Children (1-18 years): Minimal change disease most common (80-90% steroid-sensitive) 5, 6

White adults: Membranous nephropathy most common 3

African ancestry populations: Focal segmental glomerulosclerosis (FSGS) most common 3

Biopsy Decision Algorithm

Children:

Do NOT biopsy initially if age 1-12 years with typical presentation 5. Start glucocorticoids first.

  • Biopsy indicated if: Age <1 year, age >12 years, atypical features (hematuria, hypertension, low complement, elevated creatinine), steroid resistance after 4 weeks, or genetic testing concerns 5, 6

Adults:

Biopsy is typically required before treatment 7, with one critical exception:

  • Skip biopsy if: Positive serum anti-phospholipase A2 receptor (PLA2R) antibodies—this is diagnostic of membranous nephropathy 5

Initial Treatment: Children

First Episode (Steroid-Sensitive NS):

Give oral prednisone/prednisolone for either 8 weeks (4 weeks daily + 4 weeks alternate-day) OR 12 weeks (6 weeks daily + 6 weeks alternate-day) 1. Both regimens are equally effective (1B evidence).

Steroid-sensitive NS (SSNS): Complete remission within 4 weeks of standard-dose prednisone/prednisolone 2

Relapse Classification System:

Infrequently relapsing: <2 relapses in first 6 months OR <3 relapses in any 12-month period 2

Frequently relapsing: ≥2 relapses in first 6 months OR ≥3 relapses per 12 months 2

Steroid-dependent: 2 consecutive relapses during therapy (full-dose or tapering) OR within 14 days of discontinuation 2

Managing Relapses:

For infrequent relapses: Use the same glucocorticoid regimen as initial episode 1

For children with glucocorticoid toxicity: Use shorter taper and consider steroid-sparing agents earlier 1

Infection-Associated Relapses—Critical Update:

Do NOT routinely give daily glucocorticoids during upper respiratory infections to prevent relapses 1. The PREDNOS2 study showed no benefit (1C recommendation).

Exception: Consider 3 extra doses of low-dose prednisone (0.5 mg/kg/day) at URI onset ONLY if the child is already on alternate-day prednisolone AND has history of repeated infection-associated relapses with significant steroid-related morbidity 1.

Steroid-Sparing Agents

When to Use:

Initiate glucocorticoid-sparing agents for:

  1. Frequently relapsing NS with serious glucocorticoid adverse effects (1B recommendation) 1
  2. ALL children with steroid-dependent NS (1B recommendation) 1

For frequently relapsing NS without glucocorticoid toxicity: Low-dose alternate-day prednisone/prednisolone may be continued before introducing steroid-sparing agents 1

Agent Selection—No Longer First-Line vs. Alternative:

The 2025 KDIGO guideline eliminated the hierarchy of first-line versus alternative agents 1. Instead, choose based on relapse pattern:

For frequently relapsing NS (prefer):

  • Oral cyclophosphamide
  • Levamisole

For steroid-dependent NS (prefer):

  • Mycophenolate mofetil
  • Rituximab (1-4 doses, insufficient data for specific dosing recommendation)
  • Calcineurin inhibitors (tacrolimus, cyclosporine)
  • Oral cyclophosphamide (to lesser extent)

How to Initiate:

  • Patient should be in remission with glucocorticoids before starting steroid-sparing agent 1
  • Continue glucocorticoids for 2 weeks after initiating the steroid-sparing agent 1

Steroid-Resistant Nephrotic Syndrome (SRNS)

SRNS definition: Lack of complete remission within 4 weeks of daily prednisone/prednisolone at standard dose 2

Mandatory Next Steps:

  1. Genetic testing: Essential to identify monogenic causes 5, 6
  2. Kidney biopsy: Required to determine histological diagnosis 5, 6

Treatment Challenges:

SRNS management remains difficult with limited options 6. Multidrug-resistant SRNS carries high risk of progression to end-stage kidney disease 6. Consider:

  • CNIs (tacrolimus/cyclosporine)
  • B-cell-directed therapies
  • Referral to specialized center

Supportive Management (All Patients)

Edema Control:

  • Dietary sodium restriction: <2 g/day
  • Loop diuretics: Furosemide as primary agent 8
  • Monitor for intravascular volume depletion

Antiproteinuric Therapy:

  • ACE inhibitors or ARBs: Reduce proteinuria and slow progression
  • Target blood pressure control

Lipid Management:

  • Statins: For hyperlipidemia 8

Thromboembolism Prophylaxis:

Consider anticoagulation for high-risk patients, particularly membranous nephropathy 5. Risk factors include:

  • Severe hypoalbuminemia (<20 g/L)
  • Prolonged immobility
  • Membranous nephropathy specifically

Infection Prevention:

  • Pneumococcal vaccination
  • Monitor for peritonitis, cellulitis, sepsis (increased risk due to immunoglobulin loss and immunosuppression)

Long-Term Monitoring

Home Monitoring:

Train patients/families to check urine dipstick at home 6. This enables early relapse detection (3+ protein on 3 consecutive days).

Clinic Follow-Up:

  • Frequent monitoring during active disease: Weekly to biweekly
  • Stable remission: Every 3-6 months
  • Monitor for:
    • Proteinuria (uPCR)
    • Renal function (creatinine, eGFR)
    • Medication adverse effects
    • Growth parameters (children)
    • Blood pressure

Prognosis

Steroid-sensitive NS: Excellent long-term kidney outcomes 6. Many children continue relapsing into adulthood but maintain kidney function.

Steroid-resistant NS: High risk of progression to ESKD, especially if multidrug-resistant 6. Requires subspecialist co-management.

Critical Pitfalls to Avoid

  1. Do not biopsy children 1-12 years with typical presentation before steroid trial 5
  2. Do not give prophylactic steroids for every URI—PREDNOS2 showed no benefit 1
  3. Do not continue glucocorticoids alone in steroid-dependent NS—always add steroid-sparing agent 1
  4. Do not delay genetic testing in SRNS—changes management fundamentally 6
  5. Do not forget thromboembolism prophylaxis in membranous nephropathy 5
  6. Do not assume adult NS is minimal change disease—biopsy required (except PLA2R+ membranous) 7

Related Questions

What laboratory tests are needed to evaluate for nephrotic syndrome?
What is nephrotic syndrome?
In a patient with nephrotic syndrome who has edema, proteinuria, and hypoalbuminemia, what additional laboratory abnormality is typically present?
What is the appropriate evaluation and management of papilledema in a patient with nephrotic syndrome?
Which of the following is NOT a typical feature of nephrotic syndrome: proteinuria >3 g per 24 hours, hypoalbuminemia, peripheral edema, glomerular hematuria, or hyperlipidemia?
What are the risk factors, microbiologic profile, and drug susceptibility patterns in adults with bacterial community‑acquired pneumonia in northeast Nigeria?
What hydrocortisone (Solucortef) dose should be administered after starting norepinephrine (Levophed) for septic or vasodilatory shock?
Is annual human chorionic gonadotropin (hCG) monitoring necessary in a postmenopausal patient after phantom hCG has been confirmed and tumor‑marker hCG is normal?
In a patient with hypotension and bradycardia whose toxicology screen is positive for methadone, fentanyl, cocaine, and marijuana, what immediate assessment and treatment steps should be taken for possible mixed‑opioid and stimulant intoxication?
For a febrile patient taking acetaminophen, without dysuria, with a normal white blood cell count, procalcitonin 0.9 ng/mL, and a urine culture susceptible to nitrofurantoin (Macrobid), ciprofloxacin, and ampicillin, which antibiotic is the optimal choice?
What is the recommended ciprofloxacin dosing regimen and duration for an adult, including adjustments for normal renal function, renal impairment (creatinine clearance 30–50 mL/min and <30 mL/min), and intravenous administration?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.